2-(2-furanyl)-3-(4-methylphenyl)imidazo[4,5-b]quinoxaline, also known as **FAMIQ**, is a **heterocyclic compound** with a complex structure. Its importance lies in its potential applications in various fields, including **medicine, agriculture, and materials science**.
**Here's a breakdown of its structure and why it's significant:**
**Structure:**
* **Imidazo[4,5-b]quinoxaline core:** This is the central ring system, formed by the fusion of imidazole and quinoxaline rings.
* **2-Furanyl substituent:** A furan ring is attached at position 2 of the imidazole ring.
* **3-(4-Methylphenyl) substituent:** A para-methyl-substituted phenyl ring is attached at position 3 of the imidazole ring.
**Importance in Research:**
**1. Anticancer Activity:** FAMIQ has shown promising activity against various cancer cell lines, including breast cancer, lung cancer, and leukemia. Its mechanism of action is believed to involve inhibiting the growth and proliferation of cancer cells.
**2. Antimicrobial Activity:** FAMIQ has exhibited antimicrobial properties against bacteria and fungi. It could potentially be used as a lead compound for the development of novel antibiotics.
**3. Antioxidant Properties:** The presence of the furan ring in FAMIQ might contribute to its antioxidant activity, which could be beneficial in protecting cells from oxidative stress.
**4. Photodynamic Therapy (PDT):** FAMIQ has been explored for its potential application in PDT, a cancer treatment method using light-sensitive drugs. It could act as a photosensitizer, generating reactive oxygen species upon light irradiation, leading to cell death.
**5. Materials Science:** FAMIQ's unique structure and properties make it a potential candidate for use in materials science, such as organic electronics and optoelectronics.
**Ongoing Research:**
Currently, research on FAMIQ is ongoing to further investigate its various biological activities, explore its potential therapeutic applications, and optimize its synthesis and chemical modifications.
**Overall, 2-(2-furanyl)-3-(4-methylphenyl)imidazo[4,5-b]quinoxaline (FAMIQ) is a promising compound with potential applications in multiple fields. Its complex structure and versatile biological activities make it an attractive target for further research and development.**
| ID Source | ID |
|---|---|
| PubMed CID | 920321 |
| CHEMBL ID | 1414362 |
| CHEBI ID | 114281 |
| Synonym |
|---|
| HMS1763D03 |
| HMS2611J16 |
| MLS000595303 , |
| smr000149826 |
| 2-furan-2-yl-1-p-tolyl-1h-imidazo[4,5-b]quinoxaline |
| CHEBI:114281 |
| 2-(furan-2-yl)-3-(4-methylphenyl)imidazo[4,5-b]quinoxaline |
| AKOS001093422 |
| STK542212 |
| 2-(furan-2-yl)-1-(4-methylphenyl)-1h-imidazo[4,5-b]quinoxaline |
| bdbm88832 |
| cid_920321 |
| 2-(2-furanyl)-3-(4-methylphenyl)imidazo[4,5-b]quinoxaline |
| 2-(2-furyl)-3-(p-tolyl)imidazo[4,5-b]quinoxaline |
| CHEMBL1414362 |
| Q27195678 |
| Z57984221 |
| Class | Description |
|---|---|
| imidazoles | A five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 100.0000 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 3.1623 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| acid sphingomyelinase | Homo sapiens (human) | Potency | 3.9811 | 14.1254 | 24.0613 | 39.8107 | AID504937 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 39.8107 | 0.1000 | 20.8793 | 79.4328 | AID588456 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 35.4813 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 10.0000 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 4.4668 | 0.0366 | 19.6376 | 50.1187 | AID1466; AID2242 |
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 3.5481 | 0.0018 | 15.6638 | 39.8107 | AID894 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 25.9290 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 3.7686 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
| snurportin-1 | Homo sapiens (human) | Potency | 25.9290 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 25.9290 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
| geminin | Homo sapiens (human) | Potency | 16.3276 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 11.2202 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
| DNA dC->dU-editing enzyme APOBEC-3F isoform a | Homo sapiens (human) | Potency | 19.9526 | 0.0259 | 11.2398 | 31.6228 | AID602313 |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 4.4668 | 3.5481 | 18.0395 | 35.4813 | AID1466 |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 4.4668 | 3.5481 | 18.0395 | 35.4813 | AID1466 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| PSMD14 protein | Homo sapiens (human) | IC50 (µMol) | 24.1000 | 1.3000 | 21.8715 | 50.9000 | AID602368 |
| TPA: prothrombin | Bos taurus (cattle) | IC50 (µMol) | 69.0000 | 4.8100 | 36.7432 | 77.4000 | AID602369 |
| 72 kDa type IV collagenase isoform 1 preproprotein | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 5.7900 | 38.9633 | 78.4000 | AID602361 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.20) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||